- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ADAC brings PET to oncologists
ADAC Laboratories and American Diagnostic Medicine have signed an agreement with the International Oncology Network to offer PET imaging services to the network's 2000 oncologists. This agreement is an offshoot of the "First Nuclear" joint venture
ADAC Laboratories and American Diagnostic Medicine have signed an agreement with the International Oncology Network to offer PET imaging services to the network's 2000 oncologists. This agreement is an offshoot of the "First Nuclear" joint venture between ADAC and ADM.
Any International Oncology Network member can sign up for the First Nuclear program. ADAC will provide the PET scanners and trained technologists to perform diagnostic exams, along with supplies, marketing, state licensing, procedure coding, and other information. ADM will provide the facilities and administrative services.
ADAC has been developing PET scanners for five years. Three years ago, the company introduced C-PET, a dedicated whole-body scanning device. ADM runs programs that let hospitals, freestanding clinics, group practices, and other managed-care providers deliver medical imaging services.
Also this month, ADAC announced results of its second quarter 2000. Revenue was $90 million compared to $87.4 million for second quarter 1999. The company's net income for the quarter was $3.1 million compared to a net loss of $7.9 million in second quarter 1999. ADAC said the second quarter 1999 loss was due to combined pretax restructuring and pretax charges of $18 million.
ADAC received orders for 16 C-PET units during the second quarter of fiscal 2000, compared with orders for 10 units in the first quarter.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
